Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
about
From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Evolving treatments for advanced gastric cancer: appraisal of the survival trend.Continuous, low-dose capecitabine for patients with recurrent colorectal cancer.
P2860
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
@en
Low-dose capecitabine
@nl
type
label
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
@en
Low-dose capecitabine
@nl
prefLabel
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
@en
Low-dose capecitabine
@nl
P2093
P2860
P1433
P1476
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
@en
P2093
Annika Holmqvist
Jasmine Miger
Maria Albertsson
Xiao-Feng Sun
P2860
P2888
P356
10.1007/S12032-014-0870-2
P577
2014-02-08T00:00:00Z